Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis

Part of paid clinical trials in Mayfield Heights, Ohio.

Sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
Study ID
NCT07236099
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Prurigo Nodularis (PN)

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • ICP-322 — DRUG
    ICP-322 Tablets
  • Placebo — DRUG
    ICP-332 Placebo Tablets

Study Details

Evaluate the efficacy and safety of ICP-332 in participants with Prurigo Nodularis (PN)

Key Dates

Start date
Nov 27, 2025
Status verified
Dec 2025
Primary completion
Mar 31, 2027
Completion
Oct 31, 2027

Study Design

Enrollment
135 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: ICP-332 80mg
  • Experimental: ICP-332 120mg
  • Placebo Comparator: Placebo

Primary Outcome Measure

Peak pruritus-numeric rate scale (PP NRS) [ Time Frame: Baseline to week 16 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Apex Clinical Research CenterMayfield HeightsOhio44124
Jorge A Garcia-Zuazaga

Find similar trials in Mayfield Heights, OH

By research site
Apex Clinical Research Center· Mayfield Heights, OH

Related Studies